HomeCompareLZAGY vs JEPI

LZAGY vs JEPI: Dividend Comparison 2026

LZAGY yields 0.76% · JEPI yields 8.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LZAGY wins by $690.00 in total portfolio value· pulled ahead in Year 10
10 years
LZAGY
LZAGY
● Live price
0.76%
Share price
$63.41
Annual div
$0.48
5Y div CAGR
39.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.7K
Annual income
$2,840.75
Full LZAGY calculator →
JEPI
JPMorgan Equity Premium Income ETF
● Live price
8.40%
Share price
$56.68
Annual div
$4.76
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$1,528.62
Full JEPI calculator →

Portfolio growth — LZAGY vs JEPI

📍 LZAGY pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLZAGYJEPI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LZAGY + JEPI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LZAGY pays
JEPI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LZAGY
Annual income on $10K today (after 15% tax)
$64.35/yr
After 10yr DRIP, annual income (after tax)
$2,414.64/yr
JEPI
Annual income on $10K today (after 15% tax)
$714.16/yr
After 10yr DRIP, annual income (after tax)
$1,299.33/yr
At 15% tax rate, LZAGY beats the other by $1,115.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LZAGY + JEPI for your $10,000?

LZAGY: 50%JEPI: 50%
100% JEPI50/50100% LZAGY
Portfolio after 10yr
$29.3K
Annual income
$2,184.68/yr
Blended yield
7.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on LZAGY right now

LZAGY
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
4.2
Piotroski
7/9
JEPI
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LZAGY buys
0
JEPI buys
0
No recent congressional trades found for LZAGY or JEPI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLZAGYJEPI
Forward yield0.76%8.40%
Annual dividend / share$0.48$4.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR39.3%0%
Portfolio after 10y$29.7K$29.0K
Annual income after 10y$2,840.75$1,528.62
Total dividends collected$8.7K$11.7K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: LZAGY vs JEPI ($10,000, DRIP)

YearLZAGY PortfolioLZAGY Income/yrJEPI PortfolioJEPI Income/yrGap
1$10,805$105.46$11,260$840.19$455.00JEPI
2$11,710$148.35$12,641$907.94$931.00JEPI
3$12,739$209.30$14,150$978.20$1.4KJEPI
4$13,927$296.42$15,795$1,050.85$1.9KJEPI
5$15,324$421.90$17,584$1,125.74$2.3KJEPI
6$17,001$604.34$19,526$1,202.74$2.5KJEPI
7$19,064$872.88$21,628$1,281.69$2.6KJEPI
8$21,673$1,274.26$23,898$1,362.43$2.2KJEPI
9$25,076$1,885.93$26,347$1,444.79$1.3KJEPI
10← crossover$29,672$2,840.75$28,982$1,528.62+$690.00LZAGY

LZAGY vs JEPI: Complete Analysis 2026

LZAGYStock

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Full LZAGY Calculator →

JEPIETF

The fund seeks to provide the majority of the returns associated with its primary benchmark, the Standard & Poor's 500 Total Return Index (S&P 500 Index), while exposing investors to less risk through lower volatility and still offering incremental income. Under normal circumstances, the fund invests at least 80% of its assets in equity securities. It may also invest in other equity securities not included in the S&P 500 Index.

Full JEPI Calculator →
📬

Get this LZAGY vs JEPI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LZAGY vs SCHDLZAGY vs OLZAGY vs KOLZAGY vs MAINLZAGY vs JEPQLZAGY vs XYLDLZAGY vs DIVOLZAGY vs QYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.